S M Devine

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone
    S M Devine
    Siteman Cancer Center and Department of Medicine, Division of Oncology, Section of Stem Cell Transplantation, Leukemia, and Stem Cell Biology, Washington University School of Medicine, St Louis, MO, USA
    Bone Marrow Transplant 36:531-8. 2005
  2. ncbi Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates
    Steven M Devine
    Section of Hematology Oncology, Department of Surgery, University of Illinois College of Medicine, Chicago, USA
    Blood 101:2999-3001. 2003
  3. ncbi Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma
    Steven M Devine
    Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 22:1095-102. 2004
  4. ncbi Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion
    S M Devine
    Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Exp Hematol 29:244-55. 2001
  5. ncbi Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients
    L A Verkruyse
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 37:51-6. 2006
  6. ncbi The relative quiescence of hematopoietic stem cells in nonhuman primates
    N Mahmud
    Hematology/Oncology Section and Transplantation Surgery Section, Biologic Resources Laboratory, University of Illinois College of Medicine, Chicago 60607-7173, USA
    Blood 97:3061-8. 2001
  7. ncbi Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
    R Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 32:703-7. 2003
  8. ncbi Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor
    David A Hess
    Department of Internal Medicine, Division of Oncology, Hematopoietic Development and Malignancy Group, Washington University School of Medicine, 4940 Parkview Place, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 13:398-411. 2007
  9. ncbi A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation
    Thomas Fong
    Division of Oncology, Section of Leukemia and Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 13:1201-6. 2007
  10. ncbi Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo
    A Bartholomew
    Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612, USA
    Hum Gene Ther 12:1527-41. 2001

Detail Information

Publications31

  1. ncbi Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone
    S M Devine
    Siteman Cancer Center and Department of Medicine, Division of Oncology, Section of Stem Cell Transplantation, Leukemia, and Stem Cell Biology, Washington University School of Medicine, St Louis, MO, USA
    Bone Marrow Transplant 36:531-8. 2005
    ..Donor PBPC grafts mobilized with GM-CSF alone result in prompt hematopoietic engraftment despite lower CD34+ cell doses and may reduce the risk of grades II-IV acute GVHD following HLA-matched PBPC transplantation...
  2. ncbi Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates
    Steven M Devine
    Section of Hematology Oncology, Department of Surgery, University of Illinois College of Medicine, Chicago, USA
    Blood 101:2999-3001. 2003
    ..These data suggest that MSCs initially distribute broadly following systemic infusion and later may participate in ongoing cellular turnover and replacement in a wide variety of tissues...
  3. ncbi Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma
    Steven M Devine
    Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 22:1095-102. 2004
    ..We performed a phase I study assessing the safety and clinical effects of AMD3100 in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)...
  4. ncbi Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion
    S M Devine
    Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Exp Hematol 29:244-55. 2001
    ....
  5. ncbi Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients
    L A Verkruyse
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 37:51-6. 2006
    ..We conclude delaying pre-emptive therapy with ODG until whole blood QPCR> or =10 000 copies/ml is a safe and effective strategy for CMV viremia after allogeneic stem cell transplant in clinically stable patients...
  6. ncbi The relative quiescence of hematopoietic stem cells in nonhuman primates
    N Mahmud
    Hematology/Oncology Section and Transplantation Surgery Section, Biologic Resources Laboratory, University of Illinois College of Medicine, Chicago 60607-7173, USA
    Blood 97:3061-8. 2001
    ..The relative quiescence of PHSCs observed in this nonhuman primate model, in contrast to murine PHSCs, might explain the current barriers to genetic modification and ex vivo expansion of human PHSCs...
  7. ncbi Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation
    R Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110, USA
    Bone Marrow Transplant 32:703-7. 2003
    ..No patient on LDSC GCV exhibited a decline in their ANC below 500/microl and none required growth factors. LDSC GCV is extremely well tolerated and cost-effective as PT for CMV viremia following allo-PBSC transplantation...
  8. ncbi Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor
    David A Hess
    Department of Internal Medicine, Division of Oncology, Hematopoietic Development and Malignancy Group, Washington University School of Medicine, 4940 Parkview Place, St Louis, MO 63110, USA
    Biol Blood Marrow Transplant 13:398-411. 2007
    ..Thus, AMD3100 mobilized peripheral blood represents a rapidly obtained, highly repopulating source of hematopoietic progenitors for clinical transplantation...
  9. ncbi A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation
    Thomas Fong
    Division of Oncology, Section of Leukemia and Bone Marrow Transplantation, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 13:1201-6. 2007
    ..15). With a median follow-up of 18 months, relapse-free and overall survivals (OS) were comparable in both groups. In summary, in this randomized trial, the addition of HCQ to single-agent CSA had no effects on aGVHD or cGVHD or survival...
  10. ncbi Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo
    A Bartholomew
    Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612, USA
    Hum Gene Ther 12:1527-41. 2001
    ..These data demonstrate that nonhuman primate MSCs can be engineered to deliver a secreted and biologically active gene product. Therefore, human MSCs may be an effective target for future human gene therapy trials...
  11. ncbi Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
    A F Cashen
    Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Bone Marrow Transplant 39:577-88. 2007
    ..Here, we review the current state of stem cell mobilization in normal donors and discuss novel strategies for donor stem cell mobilization...
  12. ncbi Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide
    Christopher L Hallemeier
    Department of Internal Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, St Louis, Missouri, USA
    Biol Blood Marrow Transplant 12:749-57. 2006
    ..In patients with MDS, this is an effective RIC regimen for allogeneic transplantation that can be used as an alternative to other RIC or conventional conditioning regimens...
  13. ncbi Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system
    Erik R Dubberke
    Division of Infectious Diseases, Washington University School of Medicine, St Louis, MO 63110, USA
    Infect Control Hosp Epidemiol 28:208-11. 2007
    ..Patients with severe CDAD had significantly shorter median survival times and more adverse outcomes than patients with mild or moderate CDAD...
  14. ncbi Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma
    Tanya M Wildes
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:840-6. 2008
    ..Comorbidities significantly influenced TRM and OS in this retrospective cohort. Future study should focus on improving tolerability of conditioning and careful prospective evaluation of comorbidities and their association with outcomes...
  15. ncbi Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
    Steven M Devine
    Blood and Marrow Transplantation Program, Section of Hematology Oncology, University of Illinois College of Medicine, 840 South Wood Street, M C 787, Chicago, IL 60612, USA
    Blood 99:2255-8. 2002
    ..These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM...
  16. ncbi Recent advances in allogeneic hematopoietic stem-cell transplantation
    Steven M Devine
    Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine
    J Lab Clin Med 141:7-32. 2003
  17. ncbi Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation
    Ravi Vij
    Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Blood 101:2067-9. 2003
    ..This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population...
  18. ncbi Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant
    S M Devine
    Stem Cell Transplant Program, University of Illinois College of Medicine, Chicago, IL 60612, USA
    Bone Marrow Transplant 28:557-62. 2001
    ..However, the regimen may be more beneficial when applied to patients undergoing allogeneic HSC transplantation earlier in their disease course...
  19. ncbi Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA
    Br J Haematol 135:642-50. 2006
    ..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed...
  20. ncbi Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100
    Rebecca M Shepherd
    Division of Oncology, Department of Medicine, 660 S Euclid Ave, Campus Box 8007, Saint Louis, MO 63110, USA
    Blood 108:3662-7. 2006
    ..These data show that AMD3100 is a potent and rapid mobilizer of angiogenic cells and demonstrate the feasibility of obtaining and storing large numbers of angiogenic cells by leukapheresis...
  21. ncbi Mesenchymal stem cells: will they have a role in the clinic?
    Steven M Devine
    Section of Hematology Oncology, University of Illinois, College of Medicine, Chicago, USA
    J Cell Biochem Suppl 38:73-9. 2002
    ..This review focuses on the background and rationale for performing clinical studies of MSC transplantation and will discuss the potential role that MSC may play in the correction or modification of human diseases...
  22. ncbi Clinical application of hematopoietic progenitor cell expansion: current status and future prospects
    S M Devine
    Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA
    Bone Marrow Transplant 31:241-52. 2003
    ....
  23. ncbi Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
    ..This trial was registered as no. NCT00241358 at www.ClinicalTrials.gov...
  24. ncbi Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008
    ..The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections...
  25. ncbi The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation
    Mehdi Hamadani
    Blood 111:3901-2. 2008
  26. ncbi Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients
    Hillard M Lazarus
    Department of Medicine, The University Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
    Biol Blood Marrow Transplant 11:389-98. 2005
    ..The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials...
  27. ncbi Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  28. ncbi Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma
    Steven M Devine
    Blood 99:4251-2; author reply 4252. 2002
  29. ncbi The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
    Neal Flomenberg
    Thomas Jefferson University, 125 S Ninth St, Ste 801 Sheridan Bldg, Philadelphia, PA 19107, USA
    Blood 106:1867-74. 2005
    ..All study objectives were met without significant toxicity. The results demonstrate that the combination of A + G is generally safe, effective, and superior to G alone for autologous HPC mobilization...
  30. ncbi Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect
    Mehdi Hamadani
    Biol Blood Marrow Transplant 14:480-3. 2008
  31. ncbi Fatal case of protothecosis in a hematopoietic stem cell transplant recipient after infliximab treatment for graft-versus-host disease
    Jad A Khoury
    Blood 104:3414-5. 2004